Login or Register
NEW ANTIANGINAL AGENTS – FOCUS ON RANOLAZINE

Disclaimer

This programme has received an educational grant from A. Menarini Farmaceutica Internazionale Srl [AMFI]. Any comments or opinions expressed by the authors are independent of any editorial input from AMFI and do not necessarily reflect the views of AMFI.

The Cardiovascular and Cell Sciences Research Institute, St George’s University of London, London, UK.

Managing chronic stable angina pectoris continues to represent a challenge to the practicing physician. Novel anti-angina agents have been incorporated to our therapeutic arsenal in recent years. Ranolazine is one of such agents with novel mechanisms of actions. This programme focuses on the indications, contraindications and practical use of this agent in clinical practice. General practitioners, hospital consultants and clinical-academics contribute their expert views and practical suggestions in this online educational programme.

Prof Juan Carlos Kaski

Professor of Cardiovascular Science, Cardiovascular and Cell Sciences Research Institute,St George’s, University of London, UK